How it works:
Retatrutide is a triple agonist of GIP, GLP-1 and glucagon receptors, providing comprehensive metabolic regulation. It reduces appetite, improves glycaemic control and promotes significant weight loss.
Recommended for:
Clinical studies:
Trials have shown Retatrutide achieves superior weight loss (up to 24% within 48 weeks) compared to existing drugs, along with significant HbA1c improvement in diabetic patients.
The medicine is administered subcutaneously once a week. Dosage is determined individually by a healthcare professional depending on patient condition and tolerance.
Contraindications:
Side effects: